Results 151 to 160 of about 25,648 (169)

Venetoclax

Reactions Weekly, 2017
openaire   +1 more source

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

Signal Transduction and Targeted Therapy, 2020
Jeffrey W Taub, Yubin Ge
exaly  

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

Cancer Discovery, 2020
Shanshan Pei, Daniel A Pollyea, Annika Gustafson   +2 more
exaly  

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2018
John F Seymour, Thomas J Kipps, Peter Hillmen   +2 more
exaly  

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

New England Journal of Medicine, 2019
Othman Al-Sawaf, Anna-Maria Fink, Stephen Opat   +2 more
exaly  

Ibrutinib and Venetoclax for First-Line Treatment of CLL

New England Journal of Medicine, 2019
Nitin Jain, Philip A Thompson, Gautam Borthakur   +2 more
exaly  

Venetoclax–obinutuzumab combinations are effective in fit patients with CLL

Nature Reviews Clinical Oncology, 2023
exaly  

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

New England Journal of Medicine, 2018
Constantine S Tam, Mary Ann Anderson, Rishu Agarwal   +2 more
exaly  

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Lancet Oncology, The, 2020
Shaji K Kumar, Simon J Harrison, Michele Cavo   +2 more
exaly  

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2016
Andrew W Roberts, Matthew S Davids, John M Pagel   +2 more
exaly